210 filings
Page 8 of 11
8-K
za1c6y j98le06id63s
7 Mar 19
Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
4:13pm
8-K
xb8496q
1 Mar 19
Departure of Directors or Certain Officers
12:00am
424B5
gb6exeigo
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
jqmug8 uxa6mxfadc2
21 Feb 19
Prospectus supplement for primary offering
9:22pm
8-K
7mt5 pm8s
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
op8lo p4qsoz
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
p2081u23 wcq86sczq
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
kh4zgkoq2lishl9n
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
bz51xwcs8lo4
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
hvyk62h
4 Jan 19
Other Events
8:03am
8-K
vfyrlt
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
yy4355y30b2i
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
8-K
flt4630ro4cxkp6
8 Nov 18
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
7:40am
8-K
7mojl2zy
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
ab14kprtm2ur j7o2gg
1 Oct 18
Regulation FD Disclosure
12:00am
8-K
e8leu5f
4 Sep 18
Departure of Directors or Certain Officers
12:00am
8-K
g1w5jjhg0sj1qt
9 Aug 18
Ovid Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Recent Clinical Progress
12:00am
8-K
wpa os6errxgc2ovv3
6 Aug 18
Other Events
4:31pm